New Oral GLP-1 Pill Helps Adults Lose Up to 12% of Body Weight, Phase 3 Trial Finds
Orforglipron, a once-daily pill with no food or water restrictions, just posted some of the strongest weight-loss numbers ever seen in an oral drug.
Great — I now have everything I need. Let me write the article.
A daily pill. No needle. No injection-site bruising. Up to 12% of your body weight gone in 36 weeks.
That's the headline out of a new phase 3 clinical trial on orforglipron, Eli Lilly's oral GLP-1 receptor agonist — and it's the kind of result that doesn't come along often in obesity medicine.
What Just Happened
Results from the ATTAIN-1 trial, published in the New England Journal of Medicine, show that orforglipron — a small-molecule pill taken once daily — produced meaningful weight loss in adults with obesity or overweight and weight-related health conditions. According to the ATTAIN-1 trial investigators' publication in NEJM, participants lost up to approximately 12% of their body weight over the study period.
That's a significant number. For context, MedlinePlus describes obesity as a disease defined by a BMI of 30 or higher — a condition that raises risk for heart disease, type 2 diabetes, and a long list of other serious health problems. Even modest weight loss of 5–10% can meaningfully reduce those risks. Twelve percent clears that bar by a wide margin.
This isn't the first signal on orforglipron. An earlier phase 2 study — also published in the New England Journal of Medicine — showed the drug was effective in adults with obesity, establishing the foundation for the larger phase 3 program. That earlier work is indexed on PubMed here.
What Makes This Different From Other GLP-1 Drugs
Every approved GLP-1 medication right now — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro) — is an injectable. Rybelsus is technically an oral semaglutide tablet, but it comes with strict requirements: take it on an empty stomach, with no more than 4 oz of water, wait 30 minutes before eating or drinking anything else.
Orforglipron has no such restrictions. According to reporting by Pharmacy Times, the FDA approved orforglipron as the first GLP-1 pill without time, food, or water restrictions — a meaningful quality-of-life upgrade for people who struggle with injections or complex pill routines.
A 2023 systematic review and meta-analysis in the journal Metabolism — covering both orforglipron and a competing oral GLP-1 molecule — described the class as showing "promising efficacy and safety" across randomized controlled trials, though the authors noted longer-term data were still needed at that point. That review is on PubMed here.
The Maintenance Question — And a Surprising Answer
One of the persistent criticisms of GLP-1 therapy is what happens when you stop: the weight tends to come back. A separate phase 3b trial called ATTAIN-MAINTAIN tackled this head-on.
According to the ATTAIN-MAINTAIN trial published in Nature Medicine, researchers tested whether orforglipron could help people maintain weight loss after they had already lost weight on injectable tirzepatide or semaglutide. The trial is registered on ClinicalTrials.gov (NCT06584916) and is now completed.
The Guardian reported that the pill "can help people maintain weight loss after they come off jabs" — framing orforglipron not just as a first-line treatment but potentially as a step-down option after injectable therapy. That's a new use case the field hasn't had before.
How It Compares to the Competition
BioPharma Dive reported that Lilly's orforglipron beat Novo Nordisk's Rybelsus (oral semaglutide) in a head-to-head trial earlier this year. That's a meaningful competitive win — Rybelsus has been the only oral GLP-1 option available, and it's primarily approved for type 2 diabetes, not obesity.
A 2026 meta-analysis in Diabetes Technology & Therapeutics also looked at orforglipron's efficacy across people with and without diabetes, finding positive signals on both weight and blood sugar control. That paper is here.
What This Means for You
- A pill that actually works at injectable-level results is no longer theoretical — the ATTAIN-1 phase 3 data, published in NEJM, puts real numbers behind it. If you've been hesitant about injections, this is worth tracking closely with your prescriber.
- The maintenance angle matters. If you've lost weight on an injectable GLP-1 and are wondering about transitioning off, the ATTAIN-MAINTAIN trial data is directly relevant to that conversation.
- We're still early. Phase 3 results are rigorous, but long-term safety data — years, not months — will continue to accumulate. Ask your prescriber how the emerging evidence fits your specific situation.
Not medical advice. Talk to your prescriber about your situation.
